Physicochemical Properties
Molecular Formula | C23H28F3N3O3 |
Molecular Weight | 451.48 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | PPARα 0.7 μM (EC50) PPARδ 0.7 μM (EC50) PPARγ 1.8 μM (EC50) |
ln Vitro | PPAR agonist 4 (3-10 μM) dose-dependently upregulates the expression of PPARα/δ target genes CPT1A, PDK4, and ANGPTL4 in HepG2 cells, and PPARγ target genes CD36 and FABP4 in HEK293 cells [1]. |
ln Vivo | PPAR agonist 4 (3-30 mg/kg, oral, 3 weeks) can improve collagen deposition and inhibit inflammatory cell infiltration in a CCl4-induced liver fibrosis mouse model [1]. PPAR agonist 4 in SD rats |
Cell Assay |
RT-PCR[1] Cell Types: HepG2 and HEK293 Tested Tested Concentrations: 3-10 μM Incubation Duration: 12 h Experimental Results: Upregulated levels of CPT1A, PDK4 and ANGPTL4, downregulated levels of CD36 and FABP4. |
Animal Protocol |
Animal/Disease Models: CCL4-induced liver fibrosis in C57BL/6 mice[1] Doses: 3-30 mg/kg Route of Administration: p.o., once a day for 3 weeks Experimental Results: Reduced levels of collagen and α-SMA, reduced accumulation of collagen and inflammatory cell infiltration in the portal area. Upregulated the expression of PPARs target genes (Cpt1a, Cpt2, Angptl4 and Cd36). |
References |
[1]. Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis. Eur J Med Chem. 2024 Apr 5;269:116344. |
Solubility Data
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2149 mL | 11.0747 mL | 22.1494 mL | |
5 mM | 0.4430 mL | 2.2149 mL | 4.4299 mL | |
10 mM | 0.2215 mL | 1.1075 mL | 2.2149 mL |